New pill shows promise in early brain cancer trial
NCT ID NCT05023551
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 41 times
Summary
This early-phase study tests an experimental oral drug called DSP-0390 in 39 adults whose high-grade glioma (a fast-growing brain tumor) has come back after prior treatment. The main goals are to check the drug's safety and find the best dose to use in future studies. Researchers will also watch for any signs that the drug affects the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 10032, United States
-
Hokkaido University Hospital
Sapporo, Hokkaido, 060-8648, Japan
-
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, 84112, United States
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Kyoto University Hospital
Kyoto, Sakyo-ku, 606-8507, Japan
-
National Cancer Center Hospital
Chuo Ku, Tokyo, 104-0045, Japan
-
University of California at San Francisco
San Francisco, California, 94143, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DSP-0390 (an oral drug)
What this could lead to
If it works, this could point toward a new treatment option for people with recurrent high-grade glioma, a type of aggressive brain cancer.
What could go wrong
This is a very early (Phase 1) trial with only 39 participants, so it is mainly checking safety and dosing. It is too small and early to know if the drug actually helps shrink tumors or extend life.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.